AI Article Synopsis
- South Korea's mass vaccination campaign from February 26 to April 30, 2021, administered 3.8 million COVID-19 vaccine doses.
- Out of 173 suspected anaphylaxis cases reported, 44 were confirmed as actual anaphylaxis using established case definitions.
- The rates of anaphylaxis were 18.2 per million doses for Vaxzevria and 6.2 per million for Comirnaty, with symptoms typically appearing 14 minutes after vaccination, and most patients had recovered by the time of review.
Article Abstract
The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using Brighton Collaboration case definitions. The rates per million doses were 18.2 cases and 6.2 cases for Vaxzevria and Comirnaty, respectively. Median time of onset was 14 min after vaccination and most cases had recovered at the time of review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380974 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2021.26.33.2100694 | DOI Listing |
Publication Analysis
Top Keywords
south korea
8
february april
8
april 2021
8
reports anaphylaxis
4
anaphylaxis coronavirus
4
coronavirus disease
4
disease 2019
4
2019 vaccination
4
vaccination south
4
korea february
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!